Organogenesis (NASDAQ:ORGO) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Organogenesis (NASDAQ:ORGO) from a hold rating to a buy rating in a research note issued to investors on Sunday.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings raised shares of Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research report on Friday, February 27th. BTIG Research decreased their target price on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Organogenesis presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Organogenesis Price Performance

Shares of ORGO stock opened at $2.79 on Friday. The business’s fifty day moving average is $3.94 and its 200 day moving average is $4.52. The company has a quick ratio of 3.32, a current ratio of 3.62 and a debt-to-equity ratio of 0.04. The stock has a market cap of $358.91 million, a price-to-earnings ratio of 34.88 and a beta of 1.43. Organogenesis has a twelve month low of $2.61 and a twelve month high of $7.08.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.21 by $0.10. The business had revenue of $225.61 million during the quarter, compared to analyst estimates of $172.68 million. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%. Research analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

Insider Activity

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total value of $1,028,000.00. Following the transaction, the director owned 2,565,591 shares in the company, valued at $13,187,137.74. The trade was a 7.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 33.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Organogenesis

Institutional investors and hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC purchased a new position in Organogenesis in the second quarter worth about $24,804,000. Assenagon Asset Management S.A. grew its holdings in shares of Organogenesis by 69.9% during the third quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company’s stock valued at $20,488,000 after buying an additional 1,997,038 shares during the last quarter. Norges Bank purchased a new stake in shares of Organogenesis during the fourth quarter valued at approximately $5,686,000. Millennium Management LLC increased its position in shares of Organogenesis by 481.2% during the fourth quarter. Millennium Management LLC now owns 483,742 shares of the company’s stock valued at $2,506,000 after acquiring an additional 400,514 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Organogenesis by 199.4% during the fourth quarter. SG Americas Securities LLC now owns 565,501 shares of the company’s stock valued at $2,929,000 after acquiring an additional 376,623 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.